The Role of Transscleral Cyclophotocoagulation in Patients Undergoing a Boston Keratoprosthesis

Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Jan 15, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the use of a laser treatment called transscleral cyclophotocoagulation (TS-CPC) to help manage glaucoma in patients who are about to receive a Boston keratoprosthesis (KPro), a special device that replaces a damaged cornea to improve vision. Glaucoma is a common condition in these patients, and it can lead to further vision loss. The researchers want to see if giving the TS-CPC treatment before the KPro surgery can help reduce the chances of glaucoma getting worse after the procedure.

To participate in this study, you need to be an adult between the ages of 18 and 80, able to give informed consent, and scheduled for a Boston KPro. If you join, you will be randomly assigned to one of two groups to receive different types of laser treatments before your KPro surgery. After the surgery, you will have regular follow-ups to monitor your eye health and vision over the next five years. This trial aims to find out if this preventive approach can help improve outcomes for patients with both glaucoma and corneal disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults patients
• • Able to give an informed consent
• • Capable of being followed during the study
• • Candidate for the Boston keratoprosthesis type I
• Exclusion Criteria:
• • Patients younger than 18 years old or older than 80 years old
• • Unable to give an informed consent
• • Participating to another interventional glaucoma study
• • Patients who received a glaucoma surgery or procedure (glaucoma drainage device or TS-CPC treatment) 3 months before their initial visit.
• • Unable to wear a therapeutic contact lens secondary to eyelid malformation
• • Severe Ocular surface Disease with keratinization
• • Intra-ocular tumor
• • Terminal Glaucoma
• • Phthisis bulbi
• • Ocular albinism